Purify Antigen-specific B Cells From Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT05203952
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of autoantibodies directed against citrullinated proteins, called ACPAs. These antibodies are very specific to RA, and the severity of the disease is closely correlated with the level of these ACPAs, even though they appear much earlier than the clinical signs. Current treatments by biotherapies are effective but only treat the inflammatory symptoms of the disease or, on the contrary, induce a global immunosuppression with a depletion of all B lymphocytes.
Contrary to the current approaches, the CURE RA project proposes a double innovative character:
* The project aims at specifically destroying B lymphocytes expressing / or secreting ACPAs for a more specific approach to RA, without inducing immunosuppression.
* The new therapeutic molecule is entirely original and has no equivalent at present, it uses the target antigens of autoantibodies, the citrullinated peptides, as tools to destroy the pathogenic B cells that express/produce these autoantibodies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Establishment of B cell line 1 day Establishment of B cell line From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
- Secondary Outcome Measures
Name Time Method Validation of new therapeutic molecules 1 day Validation of new therapeutic molecules
Trial Locations
- Locations (1)
UH Montpellier
🇫🇷Montpellier, France